- Report
- April 2025
- 193 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 456 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 146 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 564 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 79 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 175 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- April 2025
- 250 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- March 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- March 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- February 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- February 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- February 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- April 2025
- 193 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- August 2024
- 140 Pages
Global
From €2726EUR$2,999USD£2,315GBP
- Report
- July 2024
- 136 Pages
Global
From €2726EUR$2,999USD£2,315GBP
- Report
- May 2024
- 139 Pages
Global
From €5907EUR$6,499USD£5,016GBP
- Report
- May 2024
- 134 Pages
Global
From €5907EUR$6,499USD£5,016GBP
- Report
- May 2024
- 170 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2025
- 200 Pages
Global
From €7226EUR$7,950USD£6,136GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2727EUR$3,000USD£2,316GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more